Page 15 - Area Under News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 ACCESSWIRE Up to 2,178% more CBD delivered into bloodstream* Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and development (R&D) study programs. Study HYPER-A21-1 included three new 'DehydraTECH 2.0' formulation variations designed to enable ...

News Category Global Banking & Finance Reviews Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing MELBOURNE, Australia, Jan. 21, 2021 — Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company�...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion ... Genetic Technologies LtdJanuary 21, 2021 GMT MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Ge...

 ("TRHC") (NASDAQ:TRHC) today announced the organizations have partnered to provide TRHC's market-leading Bayesian Dosing platform, DoseMeRx™, to pharmacy professionals in small and rural hospitals. TRHC's DoseMeRx is the most efficient and cost-effective means for small and rural hospitals to comply with the revised guideline for monitoring vancomycin in the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. In March 2020, the consensus vancomycin dosing guidelines from four leading pharmacy and infectious diseases professional societies – ASHP, Infect...